Research programme: bispecific antibody therapeutics - Amgen/MD Anderson Cancer Center

Drug Profile

Research programme: bispecific antibody therapeutics - Amgen/MD Anderson Cancer Center

Latest Information Update: 19 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; University of Texas M. D. Anderson Cancer Center
  • Class Bispecific antibodies; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; CD3 antigen inhibitors; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 12 Jan 2015 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top